| 前收盘价格 | 196.45 |
| 收盘价格 | 196.45 |
| 成交量 | 854,112 |
| 平均成交量 (3个月) | 1,156,031 |
| 市值 | 28,839,434,240 |
| 市盈率 (P/E TTM) | 21.03 |
| 预期市盈率 (P/E Forward) | 14.33 |
| 价格/销量 (P/S) | 2.97 |
| 股市价格/股市净资产 (P/B) | 1.58 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2026 |
| 营业毛利率 | 15.07% |
| 营业利益率 (TTM) | 28.05% |
| 稀释每股收益 (EPS TTM) | 10.12 |
| 季度收入增长率 (YOY) | 6.10% |
| 季度盈利增长率 (YOY) | -38.90% |
| 总债务/股东权益 (D/E MRQ) | 39.00% |
| 流动比率 (MRQ) | 1.44 |
| 营业现金流 (OCF TTM) | 2.58 B |
| 杠杆自由现金流 (LFCF TTM) | 3.43 B |
| 资产报酬率 (ROA TTM) | 5.43% |
| 股东权益报酬率 (ROE TTM) | 9.19% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - General (US) | 看涨 | 混合的 |
| Drug Manufacturers - General (全球的) | 看涨 | 混合的 | |
| 股票 | Biogen Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.00 |
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - General |
| 投资方式 | Mid Value |
| 内部持股比例 | 0.19% |
| 机构持股比例 | 92.79% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 14 May 2026 | CNBC | Biogen advances Alzheimer's drug to late-stage trial despite disappointing data |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合